NCT04459273Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- First submitted
- 1 Jul 2020
- Start date
- 27 Aug 2020
- Primary completion date
- 24 Jun 2025
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Thyroid cancer, Neuroendocrine tumours, Bladder cancer, Cervical cancer, Liver and biliary tract cancer
- NCT number
- NCT04459273
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 26
- From 27 Aug 2020 to the primary completion date, 24 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT
- Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data
Other
- Patient is pregnant or nursing
Who the study is looking for
- Patients with the following cancer types:
- Brain cancer
- Bladder cancer
- Urothelial cancer
- Testicular cancer
- Skin cancer
- Thyroid cancer
- Hepatocellular carcinoma
- Cholangiocarcinoma
- Thymus cancer
- Pleural cancer
- Cervical cancer
- Adrenal cancer
- Neuroendocrine tumors
- Hematologic cancer
- Cancer of Unkown Primary
- Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis
- Patients are ≥ 18 years old at the time of the radiotracer administration.
- Patient can provide written informed consent
- Patient is able to remain still for duration of imaging procedure (up to one hour)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.